AbbVie (NYSE:ABBV) Expands SKYRIZI Availability In Canada For Ulcerative Colitis Treatment
AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...
AbbVie Inc. (ABBV): Among The Stocks With At Least $10 Million In Insider Sales Recently
We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...
Nasdaq10d
AbbVie Says Skyrizi Now Available In Canada For The Treatment Of Ulcerative Colitis
(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...
Yahoo Finance3d
AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence
AbbVie's recent product approvals, such as the availability of SKYRIZI in Canada and regulatory progress on RINVOQ in Europe, possibly buoyed investor sentiment along with the anticipation of ...
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
Crain's Chicago Business11d
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...
AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence
AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...